These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 3487578)
1. Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice. Solbach W; Forberg K; Kammerer E; Bogdan C; Röllinghoff M J Immunol; 1986 Jul; 137(2):702-7. PubMed ID: 3487578 [TBL] [Abstract][Full Text] [Related]
2. L3T4+ T cells promoting susceptibility to murine cutaneous leishmaniasis express the surface marker Ly-24 (Pgp-1). Moll H; Scollay R Eur J Immunol; 1989 Feb; 19(2):307-14. PubMed ID: 2467816 [TBL] [Abstract][Full Text] [Related]
3. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. Sadick MD; Locksley RM; Tubbs C; Raff HV J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789 [TBL] [Abstract][Full Text] [Related]
4. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells. Bogdan C; Schröppel K; Lohoff M; Röllinghoff M; Solbach W Eur J Immunol; 1990 Dec; 20(12):2533-40. PubMed ID: 1980108 [TBL] [Abstract][Full Text] [Related]
5. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629 [TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A enhances elimination of intracellular L. major parasites by murine macrophages. Bogdan C; Streck H; Röllinghoff M; Solbach W Clin Exp Immunol; 1989 Jan; 75(1):141-6. PubMed ID: 2702771 [TBL] [Abstract][Full Text] [Related]
7. Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice. Milon G; Titus RG; Cerottini JC; Marchal G; Louis JA J Immunol; 1986 Feb; 136(4):1467-71. PubMed ID: 2418115 [TBL] [Abstract][Full Text] [Related]
8. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites. Liew FY; Dhaliwal JS J Immunol; 1987 Jun; 138(12):4450-6. PubMed ID: 3295049 [TBL] [Abstract][Full Text] [Related]
9. Analysis of variables associated with promotion of resistance and its abrogation in T cell-reconstituted nude mice infected with Leishmania major. Moll H; Mitchell GF J Parasitol; 1988 Dec; 74(6):993-8. PubMed ID: 3264023 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH. Liew FY; Howard JG; Hale C J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580 [TBL] [Abstract][Full Text] [Related]
11. A role for gamma delta + T cells during experimental infection of mice with Leishmania major. Rosat JP; MacDonald HR; Louis JA J Immunol; 1993 Jan; 150(2):550-5. PubMed ID: 8419488 [TBL] [Abstract][Full Text] [Related]
12. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells. Liew FY; Hale C; Howard JG J Immunol; 1982 Apr; 128(4):1917-22. PubMed ID: 6120976 [TBL] [Abstract][Full Text] [Related]
13. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033 [TBL] [Abstract][Full Text] [Related]
14. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice. Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446 [TBL] [Abstract][Full Text] [Related]
15. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. Scott P; Pearce E; Natovitz P; Sher A J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599 [TBL] [Abstract][Full Text] [Related]
16. Cell contact-mediated macrophage activation for antileishmanial defense. II. Identification of effector cell phenotype and genetic restriction. Sypek JP; Panosian CB; Wyler DJ J Immunol; 1984 Dec; 133(6):3351-7. PubMed ID: 6333458 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. Behforouz NC; Wenger CD; Mathison BA J Immunol; 1986 Apr; 136(8):3067-75. PubMed ID: 3958489 [TBL] [Abstract][Full Text] [Related]
18. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Moll H; Fuchs H; Blank C; Röllinghoff M Eur J Immunol; 1993 Jul; 23(7):1595-601. PubMed ID: 8325337 [TBL] [Abstract][Full Text] [Related]
19. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection. Liew FY; Singleton A; Cillari E; Howard JG J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786 [TBL] [Abstract][Full Text] [Related]
20. Protective effect of isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major. Cillari E; Dieli M; Lo Campo P; Sireci G; Caffarelli A; Maltese E; Millott S; Milano S; Liew FY Immunology; 1991 Sep; 74(1):25-30. PubMed ID: 1718853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]